Mirna is currently conducting a Phase 1 clinical trial of MRX34, a miR-34-based therapy and the first miRNA mimic to advance into a human clinical trial. The Phase 1 trial is treating patients with unresectable primary liver cancer or metastatic cancer with liver involvement. The Company expects to complete the clinical trial in late 2014.
The new claims complement other significant US patents awarded to Mirna over the past three years. These include composition of matter claims granted to Mirna last year (U.S. Patent No. 8,563,708), which describe multiple chemistries and structures used in therapeutic miRNA mimics, including the one used in MRX34, the Company's lead clinical candidate. Other patents previously granted relate to the therapeutic use of fifteen miRNAs in the treatment of various cancers.
"Mirna is pleased with the continued expansion of our patent portfolio, and we remain focused on developing innovative miRNA-based therapeutics for cancer patients," said
For more information, visit www.mirnarx.com.
Keywords for this news article include: Cancer, Oncology, Treatment, Legal Issues,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- SoCalGas Reaches Record Spend on Diversity Suppliers
- Senate Dems Pull All-Nighter on Global Warming
- Senators Reach Deal on Fannie Mae, Freddie Mac
- GM Recall Poses First Major Test for New CEO
- El Empleo Rebota: La Columna Cohen
- Dianne Feinstein Accuses CIA of Spying on Congress
- Swedish Journalist Nils Horner Shot Dead in Kabul
- Deborah Hersman Quits NTSB
- Job Openings Less Than Expected in January
- Bob Crow Remembered as Shrewd Champion of Union Workers